240 related articles for article (PubMed ID: 30762670)
21. Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder.
Wymer KM; Sharma V; Saigal CS; Chamie K; Litwin MS; Packiam VT; Mossanen M; Pagliaro LC; Borah BJ; Boorjian SA
J Urol; 2021 May; 205(5):1326-1335. PubMed ID: 33347775
[TBL] [Abstract][Full Text] [Related]
22. Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options.
Yates DR; Rouprêt M
BJU Int; 2010 Jul; 106(2):162-7. PubMed ID: 20201829
[TBL] [Abstract][Full Text] [Related]
23. Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.
Khaled D; Taylor J; Holzbeierlein J
Urol Clin North Am; 2020 Feb; 47(1):119-128. PubMed ID: 31757295
[TBL] [Abstract][Full Text] [Related]
24. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
25. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
26. [Systematic review on conservative treatment options in non-muscle-invasive bladder cancer patients refractory to Bacillus Calmette-Guérin instillation therapy].
Martini T; Wezel F; Löbig N; Mitterberger MJ; Colleselli D
Aktuelle Urol; 2017 Aug; 48(4):314-328. PubMed ID: 28609792
[No Abstract] [Full Text] [Related]
27. Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.
Kikuchi E; Hayakawa N; Fukumoto K; Shigeta K; Matsumoto K
Int J Urol; 2020 Feb; 27(2):108-116. PubMed ID: 31793703
[TBL] [Abstract][Full Text] [Related]
28. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Kim HS; Seo HK
Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
[TBL] [Abstract][Full Text] [Related]
29. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
Kamat AM; Lerner SP; O'Donnell M; Georgieva MV; Yang M; Inman BA; Kassouf W; Boorjian SA; Tyson MD; Kulkarni GS; Chang SS; Konety BR; Svatek RS; Balar A; Witjes JA
Eur Urol Oncol; 2020 Jun; 3(3):318-340. PubMed ID: 32201133
[TBL] [Abstract][Full Text] [Related]
30. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
33. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
34. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
[TBL] [Abstract][Full Text] [Related]
35. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
36. Definition and management of patients with bladder cancer who fail BCG therapy.
Martin FM; Kamat AM
Expert Rev Anticancer Ther; 2009 Jun; 9(6):815-20. PubMed ID: 19496718
[TBL] [Abstract][Full Text] [Related]
37. Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer.
Bree KK; Brooks NA; Kamat AM
Hematol Oncol Clin North Am; 2021 Jun; 35(3):513-529. PubMed ID: 33958148
[TBL] [Abstract][Full Text] [Related]
38. Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer.
Soria F; Giordano A; Shariat SF; Gontero P
Curr Opin Urol; 2020 Jul; 30(4):542-546. PubMed ID: 32427633
[TBL] [Abstract][Full Text] [Related]
39. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
Prasad SM; Eyre S; Loughlin KR
Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
[TBL] [Abstract][Full Text] [Related]
40. Bacillus Calmette-Guérin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know.
Moschini M; Zamboni S; Mattei A; Amparore D; Fiori C; De Dominicis C; Esperto F;
Minerva Urol Nefrol; 2019 Feb; 71(1):17-30. PubMed ID: 30421598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]